Esophageal carcinoma

Efficacy of dendritic cell-cytokine-induced killer immunotherapy plus intensity-modulated radiation therapy in treating elderly patients with esophageal carcinoma

L. Yan, Wu, M., Ba, N., Wang, L. J., Zhang, H. Q., Shi, G. Y., Zhang, Z. S., and Wang, X. J., Efficacy of dendritic cell-cytokine-induced killer immunotherapy plus intensity-modulated radiation therapy in treating elderly patients with esophageal carcinoma, vol. 14, pp. 898-905, 2015.

We investigated the clinical efficacy of adoptive cytokine-induced killer (CIK) cell and dendritic cell (DC) therapy plus intensity-modulated radiation therapy (IMRT) for treating elderly patients with esophageal carcinoma (EC). In total, 68 elderly patients with EC were randomized to receive IMRT plus DC-CIK immunotherapy (study group, N = 34) or IMRT only (control group, N = 34). Clinical efficacy, immune function, toxicity and side effects, and life quality were evaluated after treatment. The efficacy rate was significantly higher in the study group than in the control group.

Study on serum proteomic features in patients with and without recurrence or metastasis after surgical resection of esophageal carcinoma

G. B. Zheng, Gao, C. F., Wang, X. L., Zhao, G., and Li, D. H., Study on serum proteomic features in patients with and without recurrence or metastasis after surgical resection of esophageal carcinoma, vol. 13, pp. 538-545, 2014.

The purpose of this study was to identify specific bio­markers for recurrence or metastasis of esophageal carcinoma in serum of patients subjected to esophagectomy. Surface-enhanced laser desorp­tion/ionization time-of-flight mass spectrometry (SELDI-TOF-MS) combined with IMAC-Cu2+ ProteinChip array were performed for the serum protein profiling in patients after surgical resection of esophageal carcinoma. Two groups of patients were analyzed: 38 patients without recurrence or metastasis (Group 1) and 22 patients with recurrence or metastasis after resection (Group 2).

Subscribe to Esophageal carcinoma